Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure

Shekhar H. Deo, James P. Fisher, Lauro C. Vianna, Areum Kim, Anand Chockalingam, Matthew C Zimmerman, Irving H Zucker, Paul J. Fadel

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Despite standard drug therapy, sympathetic nerve activity (SNA) remains high in heart failure (HF) patients making the sympathetic nervous system a primary drug target in the treatment of HF. Studies in rabbits with pacing-induced HF have demonstrated that statins reduce resting SNA, in part, due to reductions in reactive oxygen species (ROS). Whether these findings can be extended to the clinical setting of human HF remains unclear. We first performed a study in seven statin-naïve HF patients (56 ± 2 yr; ejection fraction: 31 ± 4%) to determine if 1 mo of simvastatin (40 mg/day) reduces muscle SNA (MSNA). Next, to control for possible placebo effects and determine the effect of simvastatin on ROS, a double-blinded, placebo-controlled crossover design study was performed in six additional HF patients (51 ± 3 yr; ejection fraction: 22 ± 4%), and MSNA, ROS, and superoxide were measured. We tested the hypothesis that statin therapy decreases resting MSNA in HF patients and this would be associated with reductions in ROS. In study 1, simvastatin reduced resting MSNA (75 ± 5 baseline vs. 65 ± 5 statin bursts/100 heartbeats; P < 0.05). Likewise, in study 2, simvastatin also decreased resting MSNA (59 ± 5 placebo vs. 45 ± 6 statin bursts/100 heartbeats; P < 0.05). In addition, statin therapy significantly reduced total ROS and superoxide. As expected, cholesterol was reduced after simvastatin. Collectively, these findings indicate that short-term statin therapy concomitantly reduces resting MSNA and total ROS and superoxide in HF patients. Thus, in addition to lowering cholesterol, statins may also be beneficial in reducing sympathetic overactivity and oxidative stress in HF patients.

Original languageEnglish (US)
Pages (from-to)377-385
Number of pages9
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume303
Issue number3
DOIs
StatePublished - Aug 1 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Oxidative Stress
Heart Failure
Simvastatin
Muscles
Reactive Oxygen Species
Superoxides
Therapeutics
Cross-Over Studies
Cholesterol
Placebos
Placebo Effect
Sympathetic Nervous System
Treatment Failure
Rabbits
Drug Therapy

Keywords

  • Norepinephrine
  • Reactive oxygen species
  • Simvastatin
  • Superoxide

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. / Deo, Shekhar H.; Fisher, James P.; Vianna, Lauro C.; Kim, Areum; Chockalingam, Anand; Zimmerman, Matthew C; Zucker, Irving H; Fadel, Paul J.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 303, No. 3, 01.08.2012, p. 377-385.

Research output: Contribution to journalArticle

Deo, Shekhar H. ; Fisher, James P. ; Vianna, Lauro C. ; Kim, Areum ; Chockalingam, Anand ; Zimmerman, Matthew C ; Zucker, Irving H ; Fadel, Paul J. / Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. In: American Journal of Physiology - Heart and Circulatory Physiology. 2012 ; Vol. 303, No. 3. pp. 377-385.
@article{6c21026e1a4e4bbf9edbaa484d6ddc7e,
title = "Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure",
abstract = "Despite standard drug therapy, sympathetic nerve activity (SNA) remains high in heart failure (HF) patients making the sympathetic nervous system a primary drug target in the treatment of HF. Studies in rabbits with pacing-induced HF have demonstrated that statins reduce resting SNA, in part, due to reductions in reactive oxygen species (ROS). Whether these findings can be extended to the clinical setting of human HF remains unclear. We first performed a study in seven statin-na{\"i}ve HF patients (56 ± 2 yr; ejection fraction: 31 ± 4{\%}) to determine if 1 mo of simvastatin (40 mg/day) reduces muscle SNA (MSNA). Next, to control for possible placebo effects and determine the effect of simvastatin on ROS, a double-blinded, placebo-controlled crossover design study was performed in six additional HF patients (51 ± 3 yr; ejection fraction: 22 ± 4{\%}), and MSNA, ROS, and superoxide were measured. We tested the hypothesis that statin therapy decreases resting MSNA in HF patients and this would be associated with reductions in ROS. In study 1, simvastatin reduced resting MSNA (75 ± 5 baseline vs. 65 ± 5 statin bursts/100 heartbeats; P < 0.05). Likewise, in study 2, simvastatin also decreased resting MSNA (59 ± 5 placebo vs. 45 ± 6 statin bursts/100 heartbeats; P < 0.05). In addition, statin therapy significantly reduced total ROS and superoxide. As expected, cholesterol was reduced after simvastatin. Collectively, these findings indicate that short-term statin therapy concomitantly reduces resting MSNA and total ROS and superoxide in HF patients. Thus, in addition to lowering cholesterol, statins may also be beneficial in reducing sympathetic overactivity and oxidative stress in HF patients.",
keywords = "Norepinephrine, Reactive oxygen species, Simvastatin, Superoxide",
author = "Deo, {Shekhar H.} and Fisher, {James P.} and Vianna, {Lauro C.} and Areum Kim and Anand Chockalingam and Zimmerman, {Matthew C} and Zucker, {Irving H} and Fadel, {Paul J.}",
year = "2012",
month = "8",
day = "1",
doi = "10.1152/ajpheart.00289.2012",
language = "English (US)",
volume = "303",
pages = "377--385",
journal = "American Journal of Physiology - Renal Physiology",
issn = "0363-6127",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure

AU - Deo, Shekhar H.

AU - Fisher, James P.

AU - Vianna, Lauro C.

AU - Kim, Areum

AU - Chockalingam, Anand

AU - Zimmerman, Matthew C

AU - Zucker, Irving H

AU - Fadel, Paul J.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Despite standard drug therapy, sympathetic nerve activity (SNA) remains high in heart failure (HF) patients making the sympathetic nervous system a primary drug target in the treatment of HF. Studies in rabbits with pacing-induced HF have demonstrated that statins reduce resting SNA, in part, due to reductions in reactive oxygen species (ROS). Whether these findings can be extended to the clinical setting of human HF remains unclear. We first performed a study in seven statin-naïve HF patients (56 ± 2 yr; ejection fraction: 31 ± 4%) to determine if 1 mo of simvastatin (40 mg/day) reduces muscle SNA (MSNA). Next, to control for possible placebo effects and determine the effect of simvastatin on ROS, a double-blinded, placebo-controlled crossover design study was performed in six additional HF patients (51 ± 3 yr; ejection fraction: 22 ± 4%), and MSNA, ROS, and superoxide were measured. We tested the hypothesis that statin therapy decreases resting MSNA in HF patients and this would be associated with reductions in ROS. In study 1, simvastatin reduced resting MSNA (75 ± 5 baseline vs. 65 ± 5 statin bursts/100 heartbeats; P < 0.05). Likewise, in study 2, simvastatin also decreased resting MSNA (59 ± 5 placebo vs. 45 ± 6 statin bursts/100 heartbeats; P < 0.05). In addition, statin therapy significantly reduced total ROS and superoxide. As expected, cholesterol was reduced after simvastatin. Collectively, these findings indicate that short-term statin therapy concomitantly reduces resting MSNA and total ROS and superoxide in HF patients. Thus, in addition to lowering cholesterol, statins may also be beneficial in reducing sympathetic overactivity and oxidative stress in HF patients.

AB - Despite standard drug therapy, sympathetic nerve activity (SNA) remains high in heart failure (HF) patients making the sympathetic nervous system a primary drug target in the treatment of HF. Studies in rabbits with pacing-induced HF have demonstrated that statins reduce resting SNA, in part, due to reductions in reactive oxygen species (ROS). Whether these findings can be extended to the clinical setting of human HF remains unclear. We first performed a study in seven statin-naïve HF patients (56 ± 2 yr; ejection fraction: 31 ± 4%) to determine if 1 mo of simvastatin (40 mg/day) reduces muscle SNA (MSNA). Next, to control for possible placebo effects and determine the effect of simvastatin on ROS, a double-blinded, placebo-controlled crossover design study was performed in six additional HF patients (51 ± 3 yr; ejection fraction: 22 ± 4%), and MSNA, ROS, and superoxide were measured. We tested the hypothesis that statin therapy decreases resting MSNA in HF patients and this would be associated with reductions in ROS. In study 1, simvastatin reduced resting MSNA (75 ± 5 baseline vs. 65 ± 5 statin bursts/100 heartbeats; P < 0.05). Likewise, in study 2, simvastatin also decreased resting MSNA (59 ± 5 placebo vs. 45 ± 6 statin bursts/100 heartbeats; P < 0.05). In addition, statin therapy significantly reduced total ROS and superoxide. As expected, cholesterol was reduced after simvastatin. Collectively, these findings indicate that short-term statin therapy concomitantly reduces resting MSNA and total ROS and superoxide in HF patients. Thus, in addition to lowering cholesterol, statins may also be beneficial in reducing sympathetic overactivity and oxidative stress in HF patients.

KW - Norepinephrine

KW - Reactive oxygen species

KW - Simvastatin

KW - Superoxide

UR - http://www.scopus.com/inward/record.url?scp=84864537333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864537333&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00289.2012

DO - 10.1152/ajpheart.00289.2012

M3 - Article

C2 - 22661508

AN - SCOPUS:84864537333

VL - 303

SP - 377

EP - 385

JO - American Journal of Physiology - Renal Physiology

JF - American Journal of Physiology - Renal Physiology

SN - 0363-6127

IS - 3

ER -